Adipocyte methionine reduction promotes cancer cachexia.
🗓️ 2026-09-23
📰 Publication: Nature Cancer
Read MoreAdipocyte methionine reduction promotes cancer cachexia.Cancer-associated_cachexia
An iron-regulated methionine redox axis governs adipose browning and cancer cachexia.
Adipose browning and atrophy are early events of cachexia, a lethal metabolic disorder affecting nearly half of the population with cancer. Here, using individual-derived specimens and mouse models, we identified an iron-dependent pathway that initiates adipose browning in both physiological...
🗓️ 2026-09-23
📰 Publication: Nature Cancer
Read MoreAn iron-regulated methionine redox axis governs adipose browning and cancer cachexia.Pancreatic Cancer Disrupts Circadian Patterns of Gene Expression in Cardiorespiratory Muscles.
BACKGROUND
Cancer cachexia, a debilitating syndrome characterized by muscle wasting, significantly impacts survival in gastrointestinal cancers like pancreatic cancer. Emerging evidence suggests a link between cancer cachexia and disrupted circadian rhythms in peripheral tissues, including locomotor muscles. However, circadian dysregulation in...
🗓️ 2026-09-23
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePancreatic Cancer Disrupts Circadian Patterns of Gene Expression in Cardiorespiratory Muscles.Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia.
UNLABELLED
Cancer cachexia is a devastating wasting syndrome with no approved therapies. In this study, we identify the tumor-derived glycoprotein ADAMTSL4 as a circulating factor associated with body weight loss in preclinical cachexia models and patients with colorectal and lung cancers....
🗓️ 2026-09-01
📰 Publication: Cancer Discovery
Read MoreTumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia.Systemic Inflammatory Biomarkers and Cancer-Associated Cachexia: A Narrative Review.
Cancer-associated cachexia (CAC) is a multifactorial syndrome characterized by systemic inflammation, muscle wasting, and progressive functional decline, affecting up to 80% of patients with advanced cancer. The inconsistent diagnostic criteria limit comparability across studies and hinder translation into clinical practice....
🗓️ 2026-08-26
📰 Publication: Current Oncology
Read MoreSystemic Inflammatory Biomarkers and Cancer-Associated Cachexia: A Narrative Review.Antisense oligonucleotides against Il6ra ameliorate cancer cachexia in mice.
Mounting evidence indicates that interleukin-6 (IL-6) plays an essential role in the development of cancer cachexia. Particularly, recent work showed that IL-6 drives cancer cachexia through neurons in the area postrema of the brainstem. However, there are currently no approved...
🗓️ 2026-08-20
📰 Publication: Molecular Therapy
Read MoreAntisense oligonucleotides against Il6ra ameliorate cancer cachexia in mice.Circulating granulocyte colony-stimulating factor as a sex-unbiased global marker of lung and colorectal cancer cachexia pre-clinical models.
Cancer cachexia, affecting up to 80% of patients with advanced cancer, is characterized by metabolic and inflammatory dysregulation driven by tumour- and host-derived factors. Although cytokines are central to cachexia pathogenesis, their circulating profiles and transcriptional relevance across models and...
🗓️ 2026-08-13
📰 Publication: Experimental Physiology
Read MoreCirculating granulocyte colony-stimulating factor as a sex-unbiased global marker of lung and colorectal cancer cachexia pre-clinical models.Prostaglandin E2 drives cancer-associated cachexia.
🗓️ 2026-07-29
📰 Publication: Nature Reviews Drug Discovery
Read MoreProstaglandin E2 drives cancer-associated cachexia.Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.
Cancer cachexia is a life-threatening wasting syndrome that can be driven by tumor-derived GDF15 signaling through the brainstem-restricted receptor GFRAL. Despite its clinical importance, central genetic interventions targeting this axis remain limited. Here, we develop a potent antisense oligonucleotide (Gfral-ASO,...
🗓️ 2026-07-28
📰 Publication: Cell Reports Medicine
Read MoreTherapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.Pre-clinical cancer cachexia causes glucose hypermetabolism prior to overt weight loss.
PURPOSE
Cancer cachexia is a life-threatening complication of advanced malignancies, driven by profound systemic metabolic reprogramming and anorexia. Insulin action is markedly impaired in patients with cancer and may contribute directly to cachexia pathogenesis. However, the interplay between weight loss, food...
🗓️ 2026-07-18
📰 Publication: Molecular Metabolism
Read MorePre-clinical cancer cachexia causes glucose hypermetabolism prior to overt weight loss.Sex-divergent skeletal muscle remodeling emerges early in cancer cachexia.
Cancer cachexia is characterised by progressive skeletal muscle wasting and dysfunction, yet the early events that precede overt muscle wasting remain poorly defined. Here, we utilised a time-coursed C26 carcinoma model in male and female mice to define the pre-cachectic...
🗓️ 2026-07-17
📰 Publication: American Journal Of Physiology-Cell Physiology
Read MoreSex-divergent skeletal muscle remodeling emerges early in cancer cachexia.Pancreatic cancer cachexia promotes cardiac dysfunction through altered adrenergic signalling in the heart.
Cancer cachexia is a metabolic syndrome commonly observed in patients with pancreatic ductal adenocarcinoma (PDAC), characterized by wasting of skeletal and cardiac muscle. This condition is associated with the neurohormonal stress response and activation of the sympathetic nervous system. However...
🗓️ 2026-07-17
📰 Publication: Journal Of Physiology-London
Read MorePancreatic cancer cachexia promotes cardiac dysfunction through altered adrenergic signalling in the heart.Reframing cancer cachexia: from malnutrition to treatable disease.
🗓️ 2026-07-15
📰 Publication: Nature Reviews Endocrinology
Read MoreReframing cancer cachexia: from malnutrition to treatable disease.Differential impact of cancer- and chemotherapy-induced cachexia: a comparative analysis in a pre-clinical model of colorectal cancer by biological sex.
Cancer cachexia is a wasting condition characterized by muscle loss and reduced quality of life in cancer patients. Although biological sex differences in the progression of cancer cachexia have been increasingly recognized, their role during chemotherapy-treated cancer cachexia remains largely...
🗓️ 2026-07-15
📰 Publication: American Journal Of Physiology-Endocrinology And Metabolism
Read MoreDifferential impact of cancer- and chemotherapy-induced cachexia: a comparative analysis in a pre-clinical model of colorectal cancer by biological sex.Li-ginseng powder alleviates cancer cachexia in mice by regulating the ubiquitin-proteasome pathway and reducing inflammation.
BACKGROUND
As a debilitating syndrome, cancer cachexia (CC) manifests as ongoing weight reduction and skeletal muscle atrophy, which severely compromise patients' well-being and life expectancy, with no approved treatment available to date. Rare ginsenosides such as Rh2, Rg5, Rk1, and Rh4...
🗓️ 2026-07-03
📰 Publication: Journal Of Ginseng Research
Read MoreLi-ginseng powder alleviates cancer cachexia in mice by regulating the ubiquitin-proteasome pathway and reducing inflammation.A dietary switch promotes sensory neuron-dependent cancer-associated cachexia.
Sickness behaviors are common in cancer-associated cachexia and affect up to half of lung cancer patients. We demonstrate that among the most common cancer mutations, loss of liver kinase B1 (Lkb1) promotes the development of cachexia in preclinical models of...
🗓️ 2026-07-02
📰 Publication: Science
Read MoreA dietary switch promotes sensory neuron-dependent cancer-associated cachexia.